Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis
Previously published data was collected and a meta-analysis was conducted to precisely identify the prognostic and clinicopathological significance of soluble programmed cell death ligand-1 (sPD-L1) in patients with non-small-cell lung cancer (NSCLC). Combined hazard ratios (HRs), odds ratios and 95...
Gespeichert in:
| Veröffentlicht in: | Immunotherapy 2022-08, Vol.14 (12), p.945-956 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 956 |
|---|---|
| container_issue | 12 |
| container_start_page | 945 |
| container_title | Immunotherapy |
| container_volume | 14 |
| creator | Wang, Yan He, Haiyun |
| description | Previously published data was collected and a meta-analysis was conducted to precisely identify the prognostic and clinicopathological significance of soluble programmed cell death ligand-1 (sPD-L1) in patients with non-small-cell lung cancer (NSCLC).
Combined hazard ratios (HRs), odds ratios and 95% confidence intervals were used to assess the correlation between sPD-L1 expression and prognosis in patients with NSCLC.
A total of 11 studies with 976 patients were included in this meta-analysis. High levels of sPD-L1 were associated with poor overall and progression-free survival (HR: 2.65, 95% CI: 2.32–3.02; p |
| doi_str_mv | 10.2217/imt-2021-0238 |
| format | Article |
| fullrecord | <record><control><sourceid>futurescience_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_imt_2021_0238</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_imt_2021_0238</sourcerecordid><originalsourceid>FETCH-LOGICAL-c250t-f7ddfffcf97bd40ce69fdea883635f0986a0eea0f533cbfa3a99a676cc6e72673</originalsourceid><addsrcrecordid>eNp1kE9PwzAMxSMEEmNw5J4vEEibNmm5oYl_0iQ4gMSt8lJnBKXplKRM-_ZkDHHjZFvv2Xr-EXJZ8KuyLNS1HRIreVkwXormiMwKVXOmqqo5_uvF-yk5i_GTc1kpWc3I9iWMaz_GZDX9AjchHQ2No5tWDukmawGGAXuq0TnaI6QP6uwafM8Kaj3dQLLoU6RbmxU_ehYHcI792N3k11SD1xhuKNABEzDw4HbRxnNyYsBFvPitc_J2f_e6eGTL54enxe2S6bLmiRnV98YYbVq16iuuUbYmp2gaIUVteNtI4IjATS2EXhkQ0LYgldRaoiqlEnPCDnd1GGMMaLpNsAOEXVfwbk-ty9S6PbVuTy3724PfTGkKGHV-T2N3mDIIq63Hf3a_ASMwd0k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis</title><source>PubMed Central</source><creator>Wang, Yan ; He, Haiyun</creator><creatorcontrib>Wang, Yan ; He, Haiyun</creatorcontrib><description>Previously published data was collected and a meta-analysis was conducted to precisely identify the prognostic and clinicopathological significance of soluble programmed cell death ligand-1 (sPD-L1) in patients with non-small-cell lung cancer (NSCLC).
Combined hazard ratios (HRs), odds ratios and 95% confidence intervals were used to assess the correlation between sPD-L1 expression and prognosis in patients with NSCLC.
A total of 11 studies with 976 patients were included in this meta-analysis. High levels of sPD-L1 were associated with poor overall and progression-free survival (HR: 2.65, 95% CI: 2.32–3.02; p < 0.001 vs HR: 2.02, 95% CI: 1.24–3.29; p = 0.005). sPD-L1 level was not significantly correlated with sex, smoking status, age, Eastern Cooperative Oncology Group performance status, subtype or EGFR mutation.
High levels of sPD-L1 are a prognostic marker for poor survival in patients with NSCLC.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2021-0238</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>circulating ; clinical practice ; evidence-based medicine ; immune checkpoint inhibitors ; meta-analysis ; non-small-cell lung cancer ; PD-L1 ; prognosis ; serum</subject><ispartof>Immunotherapy, 2022-08, Vol.14 (12), p.945-956</ispartof><rights>2022 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c250t-f7ddfffcf97bd40ce69fdea883635f0986a0eea0f533cbfa3a99a676cc6e72673</citedby><cites>FETCH-LOGICAL-c250t-f7ddfffcf97bd40ce69fdea883635f0986a0eea0f533cbfa3a99a676cc6e72673</cites><orcidid>0000-0002-9233-3421</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>He, Haiyun</creatorcontrib><title>Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis</title><title>Immunotherapy</title><description>Previously published data was collected and a meta-analysis was conducted to precisely identify the prognostic and clinicopathological significance of soluble programmed cell death ligand-1 (sPD-L1) in patients with non-small-cell lung cancer (NSCLC).
Combined hazard ratios (HRs), odds ratios and 95% confidence intervals were used to assess the correlation between sPD-L1 expression and prognosis in patients with NSCLC.
A total of 11 studies with 976 patients were included in this meta-analysis. High levels of sPD-L1 were associated with poor overall and progression-free survival (HR: 2.65, 95% CI: 2.32–3.02; p < 0.001 vs HR: 2.02, 95% CI: 1.24–3.29; p = 0.005). sPD-L1 level was not significantly correlated with sex, smoking status, age, Eastern Cooperative Oncology Group performance status, subtype or EGFR mutation.
High levels of sPD-L1 are a prognostic marker for poor survival in patients with NSCLC.</description><subject>circulating</subject><subject>clinical practice</subject><subject>evidence-based medicine</subject><subject>immune checkpoint inhibitors</subject><subject>meta-analysis</subject><subject>non-small-cell lung cancer</subject><subject>PD-L1</subject><subject>prognosis</subject><subject>serum</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kE9PwzAMxSMEEmNw5J4vEEibNmm5oYl_0iQ4gMSt8lJnBKXplKRM-_ZkDHHjZFvv2Xr-EXJZ8KuyLNS1HRIreVkwXormiMwKVXOmqqo5_uvF-yk5i_GTc1kpWc3I9iWMaz_GZDX9AjchHQ2No5tWDukmawGGAXuq0TnaI6QP6uwafM8Kaj3dQLLoU6RbmxU_ehYHcI792N3k11SD1xhuKNABEzDw4HbRxnNyYsBFvPitc_J2f_e6eGTL54enxe2S6bLmiRnV98YYbVq16iuuUbYmp2gaIUVteNtI4IjATS2EXhkQ0LYgldRaoiqlEnPCDnd1GGMMaLpNsAOEXVfwbk-ty9S6PbVuTy3724PfTGkKGHV-T2N3mDIIq63Hf3a_ASMwd0k</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Wang, Yan</creator><creator>He, Haiyun</creator><general>Future Medicine Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-9233-3421</orcidid></search><sort><creationdate>20220801</creationdate><title>Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis</title><author>Wang, Yan ; He, Haiyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c250t-f7ddfffcf97bd40ce69fdea883635f0986a0eea0f533cbfa3a99a676cc6e72673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>circulating</topic><topic>clinical practice</topic><topic>evidence-based medicine</topic><topic>immune checkpoint inhibitors</topic><topic>meta-analysis</topic><topic>non-small-cell lung cancer</topic><topic>PD-L1</topic><topic>prognosis</topic><topic>serum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>He, Haiyun</creatorcontrib><collection>CrossRef</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yan</au><au>He, Haiyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis</atitle><jtitle>Immunotherapy</jtitle><date>2022-08-01</date><risdate>2022</risdate><volume>14</volume><issue>12</issue><spage>945</spage><epage>956</epage><pages>945-956</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>Previously published data was collected and a meta-analysis was conducted to precisely identify the prognostic and clinicopathological significance of soluble programmed cell death ligand-1 (sPD-L1) in patients with non-small-cell lung cancer (NSCLC).
Combined hazard ratios (HRs), odds ratios and 95% confidence intervals were used to assess the correlation between sPD-L1 expression and prognosis in patients with NSCLC.
A total of 11 studies with 976 patients were included in this meta-analysis. High levels of sPD-L1 were associated with poor overall and progression-free survival (HR: 2.65, 95% CI: 2.32–3.02; p < 0.001 vs HR: 2.02, 95% CI: 1.24–3.29; p = 0.005). sPD-L1 level was not significantly correlated with sex, smoking status, age, Eastern Cooperative Oncology Group performance status, subtype or EGFR mutation.
High levels of sPD-L1 are a prognostic marker for poor survival in patients with NSCLC.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/imt-2021-0238</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-9233-3421</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-743X |
| ispartof | Immunotherapy, 2022-08, Vol.14 (12), p.945-956 |
| issn | 1750-743X 1750-7448 |
| language | eng |
| recordid | cdi_crossref_primary_10_2217_imt_2021_0238 |
| source | PubMed Central |
| subjects | circulating clinical practice evidence-based medicine immune checkpoint inhibitors meta-analysis non-small-cell lung cancer PD-L1 prognosis serum |
| title | Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A29%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20soluble%20programmed%20cell%20death%20ligand-1%20in%20patients%20with%20non-small-cell%20lung%20cancer:%20a%20meta-analysis&rft.jtitle=Immunotherapy&rft.au=Wang,%20Yan&rft.date=2022-08-01&rft.volume=14&rft.issue=12&rft.spage=945&rft.epage=956&rft.pages=945-956&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2021-0238&rft_dat=%3Cfuturescience_cross%3E10_2217_imt_2021_0238%3C/futurescience_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |